ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CRW Craneware Plc

2,220.00
-20.00 (-0.89%)
19 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Craneware Plc LSE:CRW London Ordinary Share GB00B2425G68 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -20.00 -0.89% 2,220.00 2,180.00 2,250.00 2,230.00 2,190.00 2,190.00 560,547 16:35:09
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Prepackaged Software 174.02M 9.23M 0.2626 84.35 778.74M

Craneware plc Trading Update and Significant Contract Win (0806U)

10/07/2018 7:00am

UK Regulatory


Craneware (LSE:CRW)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Craneware Charts.

TIDMCRW

RNS Number : 0806U

Craneware plc

10 July 2018

Craneware plc

("Craneware", "the Group" or the "Company")

Trading Update and Significant Contract Win

10 July 2018 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, provides an update on trading for the year ended 30 June 2018.

The Group is pleased to announce continued outstanding performance, as it executes on its growth strategy. There has been strong underlying new sales growth that increased by approximately 100%. This includes a further significant new contract signed at the end of the year. This contract with a large healthcare provider network ('the Network') in the Eastern US is for the Company's Pharmacy ChargeLink(R) solution. Further details on the contract are provided below.

Renewals by dollar value have continued at over 100% in the period. In accordance with the Company's revenue recognition policy, the majority of the revenue resulting from both new and renewal sales successes will be recognised over future periods, adding significantly to the acceleration of the Group's long term visibility of revenue under contract.

In addition to this record sales performance, the Group expects to report increases of approximately 16% in revenue and 20% in adjusted EBITDA for the year ended 30 June 2018, extending the run of organic double digit growth delivered in prior years.

Having returned $15m to shareholders and invested a further $4m in the Employee Benefit Trust during the year, the Group's cash conversion has resulted in the cash balances returning to similar levels to those seen at the end of FY17 (FY17: $53m).

Further Significant Contract Win

Craneware has signed a significant new contract, with a large hospital network in the Eastern US, for its Pharmacy ChargeLink(R) solution. From October 2018, Craneware's solution will be rolled out to the 12 facilities across the Network. This contract is expected to deliver in excess of $6m of revenue over its initial five year term. As per the revenue recognition policy all of the revenue from this contract will be recognised in future periods.

Notice of Results

The Company will announce results for the year ended 30 June 2018 on 4 Sept 2018.

Keith Neilson, CEO of Craneware plc, commented, "These record results demonstrate the ongoing momentum we are seeing across all strata of hospitals including large and complex health systems as they embrace the realities of value-based economics within healthcare.

"The strength of our solutions and the value they deliver to our customers, allows us to support our customers as they address the challenges resulting from the continued evolution of the US Healthcare market. We are playing an increasingly strategic role in assisting healthcare providers to deliver better healthcare through sustainable financial performance, whilst mitigating operational and compliance risks.

"These factors combined with our financial strength and high levels of visible revenue for future years, gives management confidence in its continuing ability to deliver increasing stakeholder value year on year whilst investing in our future."

For further information, please contact:

 
 Craneware plc    Peel Hunt        Alma 
 +44 (0)131 550   +44 (0)20 7418   +44 (0)208 004 
  3100             8900             4217 
 Keith Neilson,   Dan Webster      Caroline Forde 
  CEO 
 Craig Preston,   George Sellar    Robyn Fisher 
  CFO 
                                   Josh Royston 
 
 

About Craneware

Craneware enables healthcare providers to improve margins and enhance patient outcomes so they can continue to provide quality outcomes for all.

Craneware is the leader in automated Value Cycle solutions that help US Healthcare provider organisations discover, convert and optimise assets to achieve best clinical outcomes and financial performance. Founded in 1999, Craneware is headquartered in Edinburgh, Scotland with offices in Atlanta and Pittsburgh employing over 300 staff. Craneware's market-driven, SaaS solutions normalise disparate data sets, bringing in up-to-date regulatory and financial compliance data to deliver value at the points where clinical and operational data transform into financial transactions, creating actionable insights that enable informed tactical and strategic decisions. To learn more, visit craneware.com and thevaluecycle.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCBRGDRBBGBGIC

(END) Dow Jones Newswires

July 10, 2018 02:00 ET (06:00 GMT)

1 Year Craneware Chart

1 Year Craneware Chart

1 Month Craneware Chart

1 Month Craneware Chart

Your Recent History

Delayed Upgrade Clock